Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$30.89 USD

30.89
2,855,238

-0.41 (-1.31%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $30.88 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Dentsply International (XRAY) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Here's Why Dentsply International (XRAY) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Dentsply International (XRAY) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.

Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 2.33% and 4.50%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 5.19% and 1.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Stay Ahead of the Game With Dentsply (XRAY) Q4 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Dentsply (XRAY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

What's in Store for West Pharmaceutical (WST) in Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.

Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.

Will Dentsply (XRAY) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

McKesson (MCK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.

GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.

Cardinal Health (CAH) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 16.67% and 1.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Cardinal Health (CAH) in Q2 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.

Cencora (COR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) fourth-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.